Foxo BioScience
在场
Foxo BioScience 是一家在股票代码 FOXO (US) 下上市的公司。
高管
查看带有其 8 名主要高管的组织结构图
Foxo BioScience 搜索最多的简介
高管在Foxo BioScience变化
- Francis Colt deWolf已作为Director加入公司 (新闻发布的2024一月26号).
- Robby Potashnick, Chief Financial Officer, 将于 20239月13 退休 (新闻发布的2023八月25号).
创建提醒
跟踪 Foxo BioScience 的高管变动
生物技术
Foxo BioScience 拥有 2,281 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Endeavor BioMedicines 刚刚宣布为 132 筹款数百万美元。 (公布2024四月25号).
- Metsera 刚刚宣布为 290 筹款数百万美元。 (公布2024四月23号).
- Histogen has filed for bankruptcy protection (公布2024四月19号).
生物技术 行业的其他推荐联系人
消息
Foxo BioScience 的最新新闻稿
- FOXO Technologies Inc. Class A Common Stock (FOXO) Press Releases | NasdaqBack ButtonSearch IconFilter Icon
- FOXO Technologies™ Collaborates with DataRobot to Pave the Way for AI-Driven Epigenetic Biomarker Research in Human Longevity
- FOXO Technologies™ Announces Second Quarter 2023 Financial Results
- Longevity Biotech Companies GERO and FOXO Technologies™ to Embark on Joint Initiative on Artificial Intelligence and Epigenetic Data to Discover Signatures of Human Health Trajectories
- FOXO Technologies Launches Bioinformatics Services to Revolutionize Epigenetic Data Analysis
- FOXO Technologies Announces Direct-to-Consumer Launch of Longevity Report Beta Product
- FOXO Technologies™ Announces First Quarter 2023 Financial Results
- FOXO Technologies™ Announces Full Year 2022 Financial Results and Recent Business Highlights
- FOXO Technologies Appoints Taylor Fay as Chief Operating Officer
- View more press releases Close
通过电子邮件
